Foreword: Preventing COVID-19 Among the Immunocompromised Population DOI Creative Commons
Michelle Willicombe

The Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 228(Supplement_1), P. S1 - S3

Published: June 21, 2023

The COVID-19 pandemic represented 1 of the more significant and unique public health challenges facing global community, particularly afflicting those with compromised immune systems. These immunocompromised individuals were readily recognized as a group at high risk infection by SARS-CoV-2 associated severe outcomes COVID-19. Although preventive strategies such vaccination are important, initial clinical vaccine trials did not enroll individuals; in-depth evaluations safety, immunogenicity, real-world these vaccines conducted in this population thereafter. As immunogenicity data among disparate emerged, adapted to address outstanding further protect entirety population. This 8-part journal supplement characterizes mRNA-based across spectrum individuals, focusing on ongoing approaches continues evolve.

Language: Английский

Perspectives on AI-based recommendations for mask-wearing and COVID-19 vaccination for transplant recipients in the post-COVID-19 era DOI Creative Commons
Oscar A. Garcia Valencia, Charat Thongprayoon, Jing Miao

et al.

Renal Failure, Journal Year: 2024, Volume and Issue: 46(1)

Published: April 7, 2024

In the aftermath of COVID-19 pandemic, ongoing necessity for preventive measures such as mask-wearing and vaccination remains particularly critical organ transplant recipients, a group highly susceptible to infections due immunosuppressive therapy. Given that many individuals nowadays increasingly utilize Artificial Intelligence (AI), understanding AI perspectives is important. Thus, this study utilizes AI, specifically ChatGPT 4.0, assess its in offering precise health recommendations tailored vulnerable population. Through series scenarios reflecting diverse environmental settings statuses December 2023, we evaluated AI's responses gauge precision, adaptability, potential biases advising high-risk patient groups. Our findings reveal 4.0 consistently recommends crowded indoor environments underscoring their elevated risk. contrast, with fewer transmission risks, outdoor areas where social distancing possible, suggests might be less imperative. Regarding guidance, strongly advocates vaccine across most kidney recipients. However, it personalized consultation healthcare providers cases patients express concerns about vaccine-related side effects, demonstrating an ability adapt based on individual considerations. While provides valuable insights into current perspective these important topics, crucial note do not directly reflect or influence policy. Nevertheless, given increasing utilization various domains, viewpoints matters essential informed decision-making future research.

Language: Английский

Citations

5
Clinical implications of COVID-19 in chronic kidney disease and end-stage kidney disease DOI
Paul Cockwell, Matthew D. Griffin

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 543 - 568

Published: Jan. 1, 2025

Language: Английский

Citations

0
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses DOI Creative Commons
Annalisa Ciabattini,

Elena Pettini,

Fabio Fiorino

et al.

EBioMedicine, Journal Year: 2025, Volume and Issue: 113, P. 105577 - 105577

Published: Feb. 4, 2025

Language: Английский

Citations

0
ORCHESTRA Delphi Consensus: Diagnostic and Therapeutic Management of SARS-CoV-2 Infection in Solid Organ Transplant Recipients DOI Creative Commons

Beatrice Tazza,

Natascia Caroccia,

Alice Toschi

et al.

Clinical Microbiology and Infection, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
SARS‐CoV‐2‐Specific Antibodies in Pediatric Solid Organ Transplant Recipients: Benefits of Additional Vaccine Doses DOI Open Access

Amanda L. Adler,

Alpana Waghmare, Jodi M. Smith

et al.

Pediatric Transplantation, Journal Year: 2025, Volume and Issue: 29(2)

Published: Feb. 24, 2025

Limited data are available regarding the development and durability of immune responses following COVID-19 infection or vaccination in pediatric solid-organ transplant (SOT) recipients. Renal, liver, intestinal recipients < 21 years age followed at Seattle Children's Hospital were enrolled from August 2020 to May 2021. Blood samples collected ~6-month intervals for up 3 tested antinucleocapsid (N) antibodies. Washington State Immunization Information System and/or medical record. Semi-quantitative anti-S IgG testing was performed on all postvaccine using Abbott Architect platform. We further evaluated a subset variant-specific quantitative binding (Meso Scale Discovery, MSD) immunoassays pseudovirus-neutralization assays. Antibody levels compared over time by vaccine category. 83 SOT median 12.5 months (IQR 7.0, 28.3). Overall, 16 (19.3%) participants had evidence SARS-CoV-2 based anti-N antibody detection. Forty-six (55%) blood sample > 14 days after receipt vaccination. Serum spike antigens (anti-S antibody) increased with number doses received as assessed both MSD Neutralizing activity significantly lower against Omicron subvariants ancestral strain. Pediatric demonstrated strong vaccination, higher 2 vaccine. Our study offers unique longitudinal response this vulnerable patient population.

Language: Английский

Citations

0
Risk of COVID‐19 infection and seizure exacerbation among patients with epilepsy during the peak of Omicron wave DOI Creative Commons
Xiuxiu Leng, Gengyao Hu, Xuan Wang

et al.

Epilepsia Open, Journal Year: 2024, Volume and Issue: 9(4), P. 1416 - 1425

Published: May 25, 2024

Abstract Objectives Existing data regarding the risk of COVID‐19 infection and its effects on seizure control in patients with epilepsy (PWE) are inconclusive. Our research aims to investigate PWE who susceptible what factors contribute exacerbation. Methods From Dec 28, 2022 Feb 19, 2023, a cross‐sectional questionnaire survey among adult was conducted. The demographics, epilepsy‐related information, COVID‐19‐related variables, outcomes after were collected. Multivariate logistic analyses performed determine associated exacerbated seizures. Results Of 1557 PWE, 829 (53.2%) infected 136 (16.4%) developed exacerbation infection. Overweight/obesity (OR 1.372, 95% CI 1.075–1.753, p = 0.011), immunocompromised 3.301, 1.093–9.974, 0.031), active 1.700, 1.378–2.097, < 0.001), antiseizure medication (ASM) polytherapy 1.314, 1.065–1.621, 0.011) Active 4.696, 2.568–8.586, 0.001) fever‐associated seizures 4.298, 95%CI 2.659–6.946, Significance overweight/obesity, immunocompromised, epilepsy, ASM at higher Once COVID‐19, Plain language summary Patients do not appear be more than general population. 16.4% had have experienced within past 12 months before tend contract often, likely experience exacerbations following

Language: Английский

Citations

2
Longitudinal Immunogenicity Study of SARS-CoV-2 mRNA Vaccines Across Subjects with Different Immunocompromising Conditions: Heterogeneity in the Immune Response and Crucial Role of the Booster Dose DOI
Annalisa Ciabattini,

Elena Pettini,

Fabio Fiorino

et al.

Published: Jan. 1, 2024

Background: Patients with primary and secondary immunodeficiencies, being more susceptible to infections, are a priority for vaccination. Here, we determined compared the immune response elicited by SARS-CoV-2 vaccination across different cohorts of immunocompromised patients in longitudinal study.Methods: In PatoVac prospective single-center study, spike-specific B cell antibody responses mRNA were haematological haemodialysis patients, hematopoietic stem solid organ transplant recipients (SOT), people living HIV (PLWH), total 598 subjects. Blood samples collected before after each vaccine administration, followed up 2 years.Findings: A responsiveness was observed first two doses, hematological, hemodialysis transplanted subjects less responsive than stem-cell PLHW. Spike-specific slower lower all except PLWH HC, but booster dose raised both that persisted years administration. Persisting low-responder subjects, especially among SOT, detected.Interpretation: Our study highlights heterogeneous pathologies, pivotal role third dose, persistence low-responders despite multiple administrations. These aspects have clinical relevance planning schedules tailored immunocompromising conditions.Funding: This work supported funds from Department Medical Biotechnology University Siena, EU within NextGenerationEU-MUR PNRR Tuscany Health Ecosystem (Project no ECS00000017-THE). Declaration Interest: MB has received honoraria support attending meetings NOVARTIS, ABVVIE, INCYTE. The authors: Annalisa Ciabattini, Elena Pettini, Fabio Fiorino, Jacopo Polvere, Simone Lucchesi, Chiara Coppola, Costagli, Gabiria Pastore, Anna Sicuranza, Monica Tozzi, Arianna Lippi, Francesca Panza, Alessandro Bucalossi, Guido Garosi, David Bennett, Sonia Bernazzali, Massimiliano Fabbiani, Montagnani Donata Medaglini declare they known competing financial interests or personal relationships could appeared influence reported this paper.Ethical Approval: studies performed compliance relevant ethical regulations protocol approved local Ethical Committee Clinical experimentation (CEAVSE; code n.19479, on 3rd March 2021 PatoVac, n. 18869 v1.0 21st December 2020 IMMUNO_COV).

Language: Английский

Citations

0
Comparison of Post-Vaccination Response (Humoral and Cellular) to BNT162b2 in Clinical Cases, Kidney and Pancreas Transplant Recipient with Immunocompetent Subjects over Almost Two Years of Parallel Monitoring DOI Creative Commons
Jarosław Walory, Iza Książek, Karolina Węgrzyńska

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(8), P. 844 - 844

Published: July 26, 2024

Background: Vaccination is one of the most effective medical interventions to prevent infectious diseases. The introduction vaccines against coronavirus acute respiratory syndrome 2 (SARS-CoV-2) was aimed at preventing severe illness and death due disease 2019 (COVID-19). Solid organ transplant recipients (SOTRs) are high risk infection with SARS-CoV-2 serious effects associated COVID-19, mainly use immunosuppressive therapies, which further cause suboptimal response COVID-19 vaccination. Aim study: We compare post-vaccination BNT162b2 in kidney–pancreas recipient, specifically immunocompetent individuals, over two years simultaneous monitoring. Methods: To determine humoral response, levels IgG IgA anti-S1 antibodies were measured. assess cellular SARS-CoV-2, released IFN-γ-S1 determinate. Results Conclusion: After primary vaccination, compared subjects, SOTR showed lower seroconversion for both antibody classes. Only additional dose produced level reached by control group after baseline During monitored period, did not achieve a positive contrast so order obtain longer protection, including immune memory, adoption booster doses vaccine should be considered.

Language: Английский

Citations

0
Foreword: Preventing COVID-19 Among the Immunocompromised Population DOI Creative Commons
Michelle Willicombe

The Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 228(Supplement_1), P. S1 - S3

Published: June 21, 2023

The COVID-19 pandemic represented 1 of the more significant and unique public health challenges facing global community, particularly afflicting those with compromised immune systems. These immunocompromised individuals were readily recognized as a group at high risk infection by SARS-CoV-2 associated severe outcomes COVID-19. Although preventive strategies such vaccination are important, initial clinical vaccine trials did not enroll individuals; in-depth evaluations safety, immunogenicity, real-world these vaccines conducted in this population thereafter. As immunogenicity data among disparate emerged, adapted to address outstanding further protect entirety population. This 8-part journal supplement characterizes mRNA-based across spectrum individuals, focusing on ongoing approaches continues evolve.

Language: Английский

Citations

0